Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs.
Cancers (Basel). 2022 Sep 19;14(18):4543. doi: 10.3390/cancers14184543. Cancers (Basel). 2022. PMID: 36139701 Free PMC article. Review.
., novel tyrosine kinase inhibitors) or subsequent intracellular signaling (e.g., PI3K/AKT/mTOR, CDK4/6 inhibitors, etc.), as well as on innovative approaches designed to attack other potential tumor weaknesses (such as immunotherapy, autophagy blockade, or targeting of ot …
., novel tyrosine kinase inhibitors) or subsequent intracellular signaling (e.g., PI3K/AKT/mTOR, CDK4/6 inhibitors, etc.), as well as …